Equities Analysts Issue Forecasts for CryoPort Q3 Earnings

Key Points

• Roth Capital has lowered its Q3 2025 earnings per share estimate for CryoPort from ($0.25) to ($0.28), reflecting a decline in projected performance.
• CryoPort reported a fiscal loss of ($0.29) EPS for the most recent quarter, which missed the consensus estimate of ($0.20) by ($0.09), despite exceeding revenue expectations with $45.45 million.
• Several financial analysts have adjusted their target prices for CryoPort, with Morgan Stanley lowering it from $8.00 to $7.00, while others like Leerink Partners set an optimistic target of $16.00.

CryoPort, Inc. (NASDAQ:CYRX - Free Report) - Analysts at Roth Capital decreased their Q3 2025 earnings per share estimates for CryoPort in a research report issued on Wednesday, August 6th. Roth Capital analyst R. Baldry now expects that the company will earn ($0.28) per share for the quarter, down from their prior forecast of ($0.25). The consensus estimate for CryoPort's current full-year earnings is ($0.99) per share. Roth Capital also issued estimates for CryoPort's Q1 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.84) EPS.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). CryoPort had a net margin of 37.21% and a negative return on equity of 10.48%. The business had revenue of $45.45 million during the quarter, compared to analyst estimates of $41.74 million.

Other equities research analysts have also issued reports about the stock. Leerink Partners upgraded shares of CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price objective on the stock in a research report on Wednesday. Guggenheim reiterated a "buy" rating and set a $10.00 price objective on shares of CryoPort in a report on Wednesday, April 16th. Morgan Stanley decreased their price objective on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. BTIG Research decreased their price objective on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, July 7th. Finally, Leerink Partnrs raised shares of CryoPort from a "hold" rating to a "strong-buy" rating in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $12.00.

CryoPort Stock Performance

CryoPort stock traded down $0.64 during midday trading on Friday, hitting $7.56. 981,876 shares of the company's stock were exchanged, compared to its average volume of 974,076. The stock has a market cap of $379.06 million, a price-to-earnings ratio of 5.68 and a beta of 1.88. The firm's 50 day simple moving average is $7.20 and its 200 day simple moving average is $6.58. The company has a debt-to-equity ratio of 0.51, a quick ratio of 5.24 and a current ratio of 5.56. CryoPort has a 12-month low of $4.58 and a 12-month high of $9.66.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC lifted its position in CryoPort by 299.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company's stock valued at $27,000 after purchasing an additional 2,729 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of CryoPort by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after acquiring an additional 2,120 shares in the last quarter. Lazard Asset Management LLC bought a new position in shares of CryoPort during the 4th quarter worth approximately $51,000. SBI Securities Co. Ltd. grew its stake in shares of CryoPort by 548,750.0% in the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock valued at $67,000 after buying an additional 10,975 shares in the last quarter. Finally, Quarry LP bought a new position in shares of CryoPort in the fourth quarter valued at $69,000. Institutional investors and hedge funds own 92.90% of the company's stock.

Insider Buying and Selling at CryoPort

In other CryoPort news, Director Ramkumar Mandalam sold 40,728 shares of the business's stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total value of $294,870.72. Following the sale, the director owned 92,328 shares of the company's stock, valued at $668,454.72. The trade was a 30.61% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jerrell Shelton sold 16,344 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $7.06, for a total transaction of $115,388.64. Following the completion of the sale, the chief executive officer directly owned 912,419 shares in the company, valued at $6,441,678.14. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 490,447 shares of company stock worth $3,337,198 in the last 90 days. 10.00% of the stock is currently owned by company insiders.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.